Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)						1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 01, 2023 USD ($)	Sep. 06, 2023 USD ($) shares	Sep. 05, 2023 USD ($)	Jun. 30, 2023 USD ($) officer	Jun. 10, 2021 shares	Nov. 30, 2021 USD ($) stockholder shares	Dec. 31, 2023 USD ($) non-employeeDirector shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2023 USD ($) non-employeeDirector $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares reserved for future issuance (in shares)							217,531,118		217,531,118		163,884,802
Granted (in shares)							0		13,097,016
Stock-based compensation expense | $							$ 26,357,000	$ 34,338,000	$ 101,198,000	$ 93,768,000
Weighted-average grant date fair values of options granted (in usd per share) | $ / shares									$ 0.87	$ 2.42
Intrinsic value of vested options exercised | $									$ 1,200,000	$ 4,400,000
Unrecognized stock-based compensation cost | $							$ 37,700,000		$ 37,700,000
Weighted average period over which unrecognized compensation is expected to be recognized									2 years 4 months 24 days
Issuance of common stock under employee stock purchase plan (in shares)							0	0	1,509,536	1,130,337
Former Lemonaid Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense | $							$ 10,800,000		$ 32,800,000
Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period						4 years
Unrecognized stock-based compensation cost | $							0		0
Common stock granted subject to vest (in shares)						3,747,027
Common stock granted subject to vest, Weighted average grant date fair value | $						$ 43,900,000
Former stockholders who were granted shares | stockholder						2
Former officers terminated | officer				1
General and administrative | Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense | $								$ 2,800,000	28,400,000	$ 8,200,000
General and administrative | Lemonaid Health, Inc. | Relinquishment Triggering Event
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense | $	$ 3,300,000
General and administrative | Lemonaid Health, Inc. | Former Lemonaid Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense | $				$ 22,000,000			3,100,000
Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Tax benefit recognized from stock option exercises | $							0	0	$ 0	0
Unvested restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance of common stock upon release of restricted stock units (in shares)									42,910,981
Weighted average period over which unrecognized compensation is expected to be recognized									2 years 7 months 6 days
Unrecognized stock-based compensation cost | $							$ 102,900,000		$ 102,900,000
Minimum | Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period									3 years
Maximum | Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period									4 years
2006 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted (in shares)									0
A&R Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation terms of award									Options under the A&R Plan have a contractual life of up to ten years. The exercise price of a stock option shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors.
Exercise price of stock options as a percentage of fair value of shares									100.00%
Non-employee directors, electing to convert cash compensation to RSUs | non-employeeDirector							4		4
Non-employee directors, electing to defer settlement of RSUs | non-employeeDirector							2		2
A&R Plan | Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance shares of increase annual percentage		5.00%	3.00%
A&R Plan | Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment award, expiration period									10 years
Number of shares of common stock received for each option exercised		1
A&R Plan | Minimum | Unvested restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period		1 year
A&R Plan | Maximum | Unvested restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period		4 years
ESPP | Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock issued and outstanding, percentage					1.00%
Potential annual increase in shares reserved for future issuance (in shares)					5,000,000
2022 AIP | Unvested restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance of common stock upon release of restricted stock units (in shares)									9,019,049
Stock-based compensation expense | $							$ (2,500,000)	$ 10,000,000	$ 4,300,000	$ 19,800,000
Other current liabilities for awards | $							$ 5,300,000		$ 5,300,000		$ 18,900,000
Class A Common Stock | 2021 Incentive Equity Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares reserved for future issuance (in shares)					136,000,000
Exchange ratio of common stock									2.293698169
Class A Common Stock | A&R Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Additional shares authorized (in shares)		75,000,000
Class A Common Stock | A&R Plan | Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares reserved for future issuance (in shares)							205,691,352		205,691,352
Class A Common Stock | A&R Plan | Lemonaid Health, Inc. | Non-Employee Directors
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Annual compensation limit | $		$ 400,000	$ 300,000
Class A Common Stock | A&R Plan | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Additional shares authorized (in shares)		75,000,000
Class A Common Stock | ESPP | Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares reserved for future issuance (in shares)					11,420,000
Number of shares issued (in shares)									4,151,849
Shares remaining available for future issuance (in shares)							11,839,766		11,839,766